MRNS - Marinus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.7800
+0.0900 (+5.33%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.6900
Open1.7000
Bid0.0000 x 1300
Ask0.0000 x 4000
Day's Range1.6800 - 1.8100
52 Week Range0.7700 - 10.5400
Volume455,771
Avg. Volume1,192,157
Market Cap93.59M
Beta (3Y Monthly)3.31
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Are Options Traders Betting on a Big Move in Marinus (MRNS) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Marinus (MRNS) Stock?

    Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.

  • Main Line pharmaceutical firm finds new CEO in-house
    American City Business Journals

    Main Line pharmaceutical firm finds new CEO in-house

    Marinus Pharmaceuticals Inc. has appointed Dr. Scott Braunstein as CEO. For the past six months Braunstein served as executive chairman of the Radnor pharmaceutical company. Marinus is focused on developing its lead drug candidate ganaxolone as a treatment for epilepsy, depression and otherneuropsychiatric disorders.

  • Here's Why Marinus Pharmaceuticals Stock Is Collapsing Today
    Motley Fool

    Here's Why Marinus Pharmaceuticals Stock Is Collapsing Today

    Wall Street is not sold on the latest clinical results.

  • Benzinga

    Marinus Sinks To 2-Year Low As Postpartum Depression Drug Found Ineffective At 28 Days

    Marinus — a pharma company that focuses on developing therapies for epilepsy, depression and other neuropsychiatric disorders — announced results from the second part of a Phase 2 Magnolia clinical trial that evaluated intravenous ganaxolone in women with postpartum depression, or PPD. The results showed that the Hamilton Rating Scale for Depression, or HAM-D17, scores at 28 days of treatment were the same as a placebo.

  • Is Marinus Pharmaceuticals Inc (MRNS) A Good Stock To Buy?
    Insider Monkey

    Is Marinus Pharmaceuticals Inc (MRNS) A Good Stock To Buy?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • 5 stocks trading at under $10 worth discovering
    MarketWatch

    5 stocks trading at under $10 worth discovering

    This seems weird, because stock price alone tells you nothing about the merits of an investment. If you turn to the stock market for thrills, you should put all your money in CDs. As market expert Martin Pring once pointed out, the stock market is designed to exploit your character flaws to take your money.

  • Announcing: Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Increased An Energizing 187% In The Last Three Years
    Simply Wall St.

    Announcing: Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Increased An Energizing 187% In The Last Three Years

    It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

  • Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study
    Zacks

    Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study

    Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.

  • Associated Press

    Marinus Pharmaceuticals: 1Q Earnings Snapshot

    On a per-share basis, the Radnor, Pennsylvania-based company said it had a loss of 24 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • How Much Of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Do Institutions Own?
    Simply Wall St.

    How Much Of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Do Institutions Own?

    Every investor in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller...

  • Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
    Zacks

    Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options

    Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

  • Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings
    Zacks

    Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings

    Oracle (ORCL) is benefiting from increasing adoption of its product portfolio and synergies from strategic buyouts.

  • Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?
    Zacks

    Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?

    Broadcom (AVGO) extensive product portfolio is likely to positively impact the to-be-reported quarter's results.

  • Benzinga

    Jefferies Sees Opportunity In Marinus Pharmaceuticals: 4 Reasons Why

    Shares of Marinus Pharmaceuticals Inc (NASDAQ: MRNS ), a micro-cap biotech focused on therapies for neuropsychiatric disorders, are likely to see upside amid some key near-term events, according to Jefferies.  ...

  • Main Line biopharm CEO stepping down
    American City Business Journals

    Main Line biopharm CEO stepping down

    A Main Line biopharmaceutical company is searching for a new chief executive officer. Marinus Pharmaceuticals of Radnor said Tuesday its CEO, Christopher Cashman, is leaving the company effective March 18 to pursue other opportunities. In an interview with the Philadelphia Business Journal, Cashman said he would classify his departure as a "mutual" decision.

  • InvestorPlace

    Zynerba Stock Is Marijuana-Adjacent Play Worth a Look

    Lately, the pharmaceutical companies are trying to use cannabis-based therapies to treat all sorts of medical conditions. Zynerba (NASDAQ:ZYNE) is another contender in this increasingly-crowded field. Whether that's a good or bad thing for Zynerba stock remains to be seen.After all, they appear to have a pretty interesting play within the space. Their ZYN002 drug candidate is, according to the company, "the first and only pharmaceutically-produced CBD formulated as a permeation‑enhanced gel for transdermal delivery".They are running studies on this CBD gel for a variety of conditions. They are investigating treatments for Fragile X, Tourette's, and seizures, among other conditions.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Monster Growth Stocks to Buy for 2019 and Beyond Understanding The Fragile X Syndrome Therapeutic LandscapeFragile X Syndrome is a relatively rare condition occurring in roughly 1 out of every 4,000 boys and 1 out of every 8,000 girls. Researchers believe that the condition is caused by a DNA defect. Fragile X often presents symptoms in children by age 2 including intellectual disability and physical characteristics such as long face and a prominent jaw.It is sometimes a complicated diagnosis as Fragile X can look like other developmental disorders. Many Fragile X children have Attention Deficit Disorder. Additionally, many exhibit features of autism disorders. Furthermore, a significant number of Fragile X patients have frequent seizures.This leads to an interesting position for Zynerba. The company states that there are no approved drug therapies for Fragile X. However, it notes that doctors use various drugs off-label to treat various Fragile X symptoms. That makes sense, as there are treatments for things such as seizures.Directly, as far as competition, Zynerba notes that Neuren Pharmaceuticals, Ovid Therapeutics (NASDAQ:OVID) and Marinus Pharmaceuticals (NASDAQ:MRNS) are all active in the research space seeking a treatment directly for Fragile X syndrome.That's not all. Zynerba has focused on the treatment of seizures in particular. Within that particular space, it faces cannabinoid-based competition on several fronts. GW Pharma (NASDAQ:GWPH), with its more than $4 billion market cap, is targeting this space and is widely thought of as a leader in cannabinoid research.Additionally, Insys (NASDAQ:INSY) is researching CBDs for seizures and infantile spasms as well. So, should Zynerba's ZYN002 be a clinical success, it won't necessarily be the first or best therapy that reaches the market. Why Zynerba Stock Popped RecentlyOn January 28th, Zynerba stock shot up 30% to reach $4.80. In subsequent days, it rallied further, reaching as high as the $6 mark. What happened on Jan. 28 that set the rally in motion? There doesn't appear to be much in the way of hard news, but the company did give a high-profile presentation and it appears this set investor enthusiasm in motion.In this presentation, the company confirmed that things are moving along as planned for its combination Phase 2/3 CONNECT trail for Fragile X syndrome. Zynerba also expects to release results for its Phase 2 trial for developmental and epileptic encephalopathies in the latter half of 2019.To add to that, Zynerba remains in reasonably strong financial position. The company reported $59.8 million in cash as of December 31st, 2018.Given its current burn rate, that should give Zynerba funds to continue its current research through the second half of 2020. While Zynerba will have to raise more funds at some point, it still has plenty of time to deliver its crucial trial results later in 2019 before going back to the market for more money. The CBD FactorIt's difficult to consider ZYNE stock without thinking about the X factor here: investor enthusiasm for marijuana-related stocks. Since late December the Alternative Harvest (NYSEARCA:MJ) marijuana ETF has ripped 50% higher off the lows. Stocks like Aphria (NYSE:APHA) and Canopy Growth (NYSE:CGC) are soaring almost every day.Zynerba itself hadn't participated in this enthusiasm, at least not until recently. However, that may be changing. Recently, famous TV host Jim Cramer talked up so-called "marijuana-adjacent" biotech firms as stocks with big potential in 2019.Cramer said:"These are not pot companies. They are drug companies focused on developing artificial cannabinoids that mimic what cannabis does to your body […] As we get more and more data showing the efficacy of medicinal marijuana, I think more investors will embrace actual medicines that do the same thing as marijuana, but they do it more reliably."With ZYNE stock, you are getting a call option on this thesis playing out later in 2019. Zynerba Stock VerdictI rarely invest in clinical stage biotech companies. It's a difficult industry; far more companies fail than succeed. Be careful with these sorts of stocks and don't invest more than you can afford to lose.That said, Zynerba has an interesting drug candidate, and is certainly positioned in a hot sector of the market. With plenty of cash to make it into mid-2020, and key data coming before then, ZYNE stock has plenty of speculative value for active traders.One upcoming catalyst to watch out for. On February 11th, CEO Armando Anido will be giving a presentation at the 2019 BIO CEO and Investor Conference. With ZYNE stock remaining volatile in recent days, any further data releases or business updates in this presentation could cause a big move in Zynerba shares.At the time of this writing, Ian Bezek held no positions in any of the aforementioned securities. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Are These 7 Dividend Aristocrats ETFs Fit for a King? * 7 of the Best Emerging Markets Stocks to Buy * 5 Gold Stocks That Should Glitter in 2019 Compare Brokers The post Zynerba Stock Is Marijuana-Adjacent Play Worth a Look appeared first on InvestorPlace.

  • Hedge Funds Are Crazy About Marinus Pharmaceuticals Inc (MRNS)
    Insider Monkey

    Hedge Funds Are Crazy About Marinus Pharmaceuticals Inc (MRNS)

    Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don’t make them change their opinion towards a company. This time it may be different. During the first 6 weeks of the fourth quarter we observed increased volatility and small-cap stocks underperformed […]

  • Marinus Pharmaceuticals plans $45M stock sale
    American City Business Journals

    Marinus Pharmaceuticals plans $45M stock sale

    Based in Radnor, Marinus Pharmaceuticals is studying a potential treatment for postpartum depression and acute epilepsy.

  • Here's Why Marinus Pharmaceuticals Is Sinking Today
    Motley Fool

    Here's Why Marinus Pharmaceuticals Is Sinking Today

    A secondary offering on the way isn't what investors wanted to hear.

  • Benzinga

    The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 11) Imprimis Pharmaceuticals Inc (NASDAQ: IMMY ) OvaScience ...

  • Benzinga

    Marinus Pharma's Postpartum Depression Candidate Aces Midstage Trials

    A handful of micro-cap stocks were making moves Monday, with the release of clinical trial results being the catalyst. Marinus said the Phase 2 trials that evaluated intravenous and oral ganaxolone for women with postpartum depression, or PPD, produced positive results.

  • Granite Point Capital’s Returns, AUM, and Holdings
    Insider Monkey

    Granite Point Capital’s Returns, AUM, and Holdings

    Warren Lammert founded Granite Point Capital, a long/short hedge fund with a focus on small-cap companies, in January 2004. The fund is headquartered in Boston, Massachusetts, and Mr. Lammert is its portfolio manager. Prior to launching his own fund, Warren Lammert honed his investment acumen for 14 years at Janus Capital Management LLC as a […]

  • Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock?
    Zacks

    Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock?

    Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

  • Associated Press

    Marinus Pharmaceuticals: 3Q Earnings Snapshot

    The Radnor, Pennsylvania-based company said it had a loss of 27 cents per share. Marinus Pharmaceuticals shares have dropped 38 percent since the beginning of the year. The stock has dropped 16 percent ...